MedWatch

Bavarian-CEO: We have the financial position for spending more capital

The prospect of lower revenue but unchanged R&D costs means that Bavarian Nordic will need to spend money from the company's capital stock in 2018. However, due to the company's cash preparedness, it should not cause worry, says the CEO.

Adm. direktør Paul Chaplin, Bavarian Nordic

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Sunstone-selskab nærmere svensk hovedbørs

Det svenske biotekselskab Cantargia fortsætter bestræbelserne mod at blive noteret på den svenske hovedbørs Nasdaq Stockholm og lever nu op til forudsætninger for dette.

Related articles